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Abstract
Background: Mycoplasma hyopneumoniae (M. hyopneumoniae) is the primary agent of enzootic pneumonia in pigs.
Pigs are often infected with different M. hyopneumoniae strains. This study assessed the efficacy of vaccination against
experimental infection with two genetically different M. hyopneumoniae strains in weaned piglets. At 33 days of age
(D0), 45 M. hyopneumoniae-free piglets were randomly assigned to three different groups: 1) negative control group
(NCG; n = 5): not vaccinated, not infected, 2) positive control group (PCG; n = 20): not vaccinated, infected, and 3)
vaccination group (VG; n = 20): single vaccination with an inactivated whole-cell M. hyopneumoniae vaccine
(Hyogen®, Ceva) (D1), infected. The PCG and VG were endotracheally inoculated with 7 × 107 CCU in 7 ml of
the highly virulent M. hyopneumoniae strain F7.2C (D24) and 7 × 107 CCU in 7 ml low virulent strain F1.12A
(D25). A respiratory disease score (RDS) was assessed from D24 until D53. At D53 (euthanasia), macroscopic
lung lesions (MLL) were scored, log copies of M. hyopneumoniae DNA (qPCR) and IL-1 and IL-6-concentrations
(ELISA) on bronchoalveolar lavage fluid were determined.
Results: The RDS and MLL at euthanasia were respectively 0, 1.20 and 0.55 (P < 0.001) and 0, 7.56 and 0.68 (P < 0.001)
for NCG, PCG and VG, respectively. The qPCR results for PCG and VG were 3.99 and 1.78 log copies (P < 0.001),
respectively, with a significant difference between PCG and VG. The IL-1 and IL-6 results at euthanasia for NCG, PCG
and VG were 17.61, 1283.39 and 53.04 pg/ml (P < 0.001) and 148.10, 493.35 and 259.80 pg/ml (P = 0.004), respectively
with a significant difference between PCG and VG.
Conclusions: Vaccination with Hyogen® in pigs was efficacious against an experimental challenge with both a low and
highly virulent M. hyopneumoniae strain as the vaccinated pigs coughed significantly less, and showed significantly less
lung lesions compared to the non-vaccinated challenged pigs: the vaccinated animals showed a 52.9% lower RDS and
91.0% lower MLL compared to the PCG. In the bronchoalveolar lavage fluid collected at the necropsy of the vaccinated
pigs, a significantly lower amount of M. hyopneumoniae-DNA and a significantly lower IL-1 and IL-6 concentration was
found compared to the pigs of the PCG.
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Background
Mycoplasma hyopneumoniae (M. hyopneumoniae) is the
causative agent of enzootic pneumonia [1]. The disease
has a worldwide impact on intensive swine production
and causes substantial losses due to reduced growth of
the pigs, poor feed conversion ratio, higher antimicrobial
use and increased susceptibility to secondary respiratory
agents [1–3]. Previous research has shown that most
pigs are infected with more than one M. hyopneumoniae
strain [4, 5], and recently, Michiels et al., [6] showed that
a higher severity and prevalence of Mycoplasma-like
lung lesions was found in batches of slaughter pigs with
detection of more than one M. hyopneumoniae strain [6].
It is generally accepted that control of M. hyopneumoniae
is critical for reducing economical losses in infected swine
operations [7]. This is achieved by optimizing housing
conditions, management practices, antimicrobial therapy
and vaccination against M. hyopneumoniae [8]. It is
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estimated that 70% of swine herds are practising
vaccination against M. hyopneumoniae worldwide [9].
Vaccination reduces clinical signs, lung lesions and im-
proves performance, although colonization is not prevented
and there is no significant reduction in transmission
[3, 8, 10–12]. The benefits obtained through vaccination
can vary from herd to herd [13]. Most commercially avail-
able bacterin vaccines are based on an adjuvanted whole-
cell preparation of an inactivated M. hyopneumoniae
strain [8]. This strain is mostly the J-strain of M. hyopneu-
moniae, which was isolated in 1958 [14, 15]. Recently a
commercial bacterin became available, using M. hyopneu-
moniae strain 2940, isolated in the 1999’s from a farm in
the United States facing a severe outbreak of enzootic
pneumonia. Also, most vaccination studies so far used one
single strain for experimental infection. As most pigs are
infected with more than one M. hyopneumoniae strain
[4–6], it may be more appropriate to challenge the pigs
with different M. hyopneumoniae strains.
The aim of the present study was to determine the
efficacy of a commercial vaccine (Hyogen®) against an
experimental challenge with two genetically different
(low and highly virulent) M. hyopneumoniae strains.
Methods
Study animals and experimental design
The study was performed after approval by the Ethical
Committee for Animal Experiments of the Faculty of
Veterinary Medicine, Ghent University (approval number
EC2014/165). Forty-five M. hyopneumoniae-free Rattrelow-
Seghers (RA-SE Genetics NV, Ooigem, Belgium) piglets
were enrolled in the study. The herd of origin has been free
of M. hyopneumoniae for many years based on repeated
serological testing, absence of clinical signs and pneumonia
lesions, and nPCR testing on tracheobronchial swabs. The
piglets were free of following pathogens as well: porcine re-
productive and respiratory syndrome virus, Pasteurella
multocida and Actinobacillus pleuropneumoniae. The pig-
lets were weaned at 28 days of age and moved to the ex-
perimental facilities of the Faculty of Veterinary Medicine,
Ghent University, Belgium. They were housed in experi-
mental chambers with absolute filters (HEPA U15) and
were fed ad libitum using a non- antimicrobial supple-
mented diet. At 33 days of age (D0), the piglets were ran-
domly allocated to three different groups (D0): 1) negative
control group (NCG; n = 5): not vaccinated, not in-
fected, 2) positive control group (PCG; n = 20): not
vaccinated, infected, and 3) vaccination group (VG;
n = 20): single vaccination with a one- dose commer-
cial vaccine (Hyogen®, CEVA Santé Animale, Libourne
Cedex, France) (D1), infected.
Hyogen® is a whole-cell bacterin based on strain BA
2940–99, oil adjuvanted with paraffin and Escherichia
coli J5 LPS with thiomersal as excipient. The animals of
the VG were intramuscularly vaccinated with two ml of
the commercial vaccine. The animals of the PCG and
NCG were injected intramuscularly with two mL of
phosphate-buffered saline (PBS).
Mycoplasma hyopneumoniae strains and challenge
infection
The highly virulent F7.2C and the low virulent M. hyop-
neumoniae strain F1.12A were used for challenge infec-
tion [16]. The pigs were anesthesized with 0.22 ml/kg
of a mixture of Zoletil 100® (Virbac, Louvain la Neuve,
Belgium) and Xyl-M® 2% (VMD, Arendonk, Belgium).
The pigs of the PCG and VG were endotracheally inoc-
ulated with 7 × 107 CCU in 7 ml inoculum of strain
F7.2C at D24 and with 7 × 107 CCU in 7 ml inoculum
of strain F1.12A at D25. Pigs of the NCG were endotra-
cheally inoculated with 7 ml sterile culture medium (Friis
medium) at D24 and D25. At four weeks post-inoculation
(PI) (D53), all piglets were euthanized. Therefore, deep an-
aesthesia was applied by intramuscularly administrating
0.3 ml/kg of a mixture of Zoletil 100® (Virbac, Louvain la
Neuve, Belgium) and Xyl-M® 2% (VMD, Arendonk,
Belgium), followed by exsanguination.
Clinical and performance parameters
The piglets were observed for at least half an hour daily
from D0 until D53. Body condition, appetite, manure
consistence, and presence of dyspnea or tachypnea
were evaluated. A respiratory disease score (RDS) was
recorded daily by the same person at eight a.m. from
D1 until D53 and could range from 0 to 6 with 0 (no
coughing), 1 (mild coughing after encouraged move), 2
(mild coughing in rest), 3 (moderate coughing after
encouraged move), 4 (moderate coughing in rest), 5
(severe coughing after encouraged move), 6 (severe
coughing in rest) [17]. The daily RDS values were aver-
aged for the following periods: D1- D23, D24– D53,
D1-D53. All pigs were weighed at D0, the day of the
first inoculation (D24) and the day of euthanasia (D53),
to calculate the anesthesia dose discussed above. The
pigs were weighed at D0, D24 and D53 (g). The average
daily gain (ADG) (g/pig/d) from day 0–24, 24–53 and
from day 0–53 was calculated according to Del Pozo
Sacristán et al. (2014), [18] by subtracting the starting
weights from the final weights divided by the number
of days during the respective periods.
Macroscopic and histopathologic lung lesions
The lungs were collected and scored for macroscopic
lung lesions (MLL) (0–35) according to Hannan et al.
(1982) [19]. Samples from the right apical, cardiac
and diaphragmatic lung lobe were collected. If lesions
were present, the samples were collected from the
border of a lesion. Samples were fixated in 10%
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neutral formalin and processed and embedded in par-
affin for histopathological examination. The samples
were stained with hematoxylin and eosin and scored
using light microscopy according to the degree of
peribronchiolar and perivascular lymphohistiocytic in-
filtration and nodule formation (cuffing) [20]. The
scoring system ranged from 1 to 5 with 1) limited in-
filtration of macrophages and lymphocytes around
bronchioles, with airways and alveolar spaces free of
cellular exudates; score 2) light to moderate infiltrates
with mild diffuse cellular exudates into airways; score
3, score 4 and score 5 (respectively mild (score 3),
moderate (score 4) and severe (score 5) lesions char-
acteristic of broncho-interstitial pneumonia, centered
around bronchioles but extending to the interstitium,
with lymphofollicular infiltration and mixed inflam-
matory cell exudates. Scores 1 and 2 are considered
not to be related with M. hyopneumoniae infection,
while scores 3 to 5 are presumptive of a M. hyopneu-
moniae infection. The percentage of lung area occu-
pied by air (percentage air) was examined by means
of an automated image analysis system (Leica applica-
tion suite AF Lite (Diegem, Belgium) and image J
(Bethesda, Maryland, USA)) [21]. This parameter is
inversely proportional to the lymphohistiocytic infil-
tration in the lung tissue and the intrabronchiolar-
and bronchial exudate.
Quantitative PCR for f M. hyopneumoniae
Bronchoalveolar lavage fluid was collected from all
animals two weeks PI (D39) by inserting a catheter
(Portex® Dog Catheter with Female Luer Mount, Smiths
Medical International Ltd. Kent, United Kingdom) in
the trachea by means of a mouth gag and whilst snaring
the pigs. Next, the lungs were flushed with 20 mL
sterile PBS to collect the bronchoalveolar lavage fluid.
Additionally, during necropsy (D53), bronchoalveolar
fluid was collected from the left part of the lung before
collection of the histopathological samples by flushing
the head bronchus of the left part of the lung with
20 mL sterile PBS. The bronchoalveolar lavage fluid
was divided into seven aliquots and stored at −70 °C
awaiting analysis. From one aliquot of the bronchoalve-
olar lavage samples, DNA was extracted with the QIA-
GEN protocol (QIAGEN, DNeasy Blood & Tissue kit,
Belgium) and quantitative PCR (qPCR) was performed
as previously described to detect the numbers of M.
hyopneumoniae organisms [22]. A tenfold dilution
series of M. hyopneumoniae DNA of strain F7.2C was
used to convert the threshold values to the number of
M. hyopneumoniae organisms. Values below the dilu-
tion of 1.50 × 101 (1.18 log copies) were considered as
negative.
Immunological parameters on bronchoalveolar lavage
fluid
M. hyopneumoniae-specific antibodies in bronchoalveolar
lavage fluid
The isotype of M. hyopneumoniae-specific antibodies in
bronchoalveolar lavage fluid collected at D39 and D53
was determined via an indirect ELISA (expressed in op-
tical density “OD”-values) according to the protocol of
Bereiter et al. [23, 24]. Briefly, a Nunc Maxisorp® flat-
bottom 96 well plate (eBioscience, Vienna, Austria) was
coated with Tween® 20 extracted M. hyopneumoniae an-
tigens on which the bronchoalveolar lavage fluid (D39,
D53) was added, undiluted. Peroxidase labeled goat anti-
porcine Ig A or Ig G polyclonal antibodies (Bethyl
Laboratories, Texas, TX, USA) were added and the OD
at 450 nm was measured.
Cytokines in bronchoalveolar lavage fluid
The bronchoalveolar lavage fluid collected at D39 and
D53 was tested undiluted for presence of porcine TNF-α
(TNF-α Swine Antibody Pair, Invitrogen), IL-1 (Porcine
IL-1 beta/IL-1F2 DuoSet, R&D Systems) and IL-6
(Porcine IL-6 DuoSet, R&D Systems). A sandwich ELISA
was performed according to the manufacturers’ recom-
mendations. The sample reactions were measured using
OD at 450 nm and quantified by the use of a standard
curve as described in the manual.
Serology
At D1, D24 and at euthanasia (D53), blood was collected
from all pigs and tested for the presence of antibodies
against M. hyopneumoniae with a blocking ELISA
(IDEIA™ Mycoplasma hyopneumoniae EIA kit, Oxoid
Limited, Hampshire, UK), according to the protocol man-
ual. Sera with optical density < 50% of the average value of
the OD-buffercontrol were considered to be positive. All
values above or equal to 50% of the average value of the
OD-buffercontrol were classified as negative.
Routine bacteriological culture on bronchoalveolar lavage
fluid
For the bacteriological examination, ten μL of broncho-
alveolar lavage fluid collected on D53 of each pig was in-
oculated on Columbia agar supplemented with 5% sheep
blood (Oxoid, Hampshire, UK) with a Staphylococcus
pseudintermedius streak [25]. Plates were incubated
overnight in a 5% CO2-enriched environment at 35 °C
for 48 h for identification of respiratory bacteria in the
lungs.
Statistical analysis
Descriptive statistics were performed in order to check
the normality of the data. One-way analysis of variance
(ANOVA) was used to analyse weight and ADG. Repeated
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measurements ANOVA was performed to analyze the
RDS data. Scheffé’s post hoc test was used to make pair-
wise group comparisons. The parameters MLL, histo-
pathological lesions, percentage air analysis, ELISA M.
hyopneumoniae, TNF-α, IL-1, IL-6, Ig A, Ig G and qPCR
results were analyzed using a non-parametric Kruskal-
Wallis, as the data did not fulfil the assumptions of nor-
mality. Theses analyses were performed with SPSS 22 for
Windows (SPSS inc. Illinois, USA). Percentage of sero-
positive pigs and percentage of pigs testing positive with
qPCR in each group were analyzed using binomial logistic
regression (R version 3.3.1) [26]. Results were considered
to be statistically significant when P < 0.05.
Results
No animals died during or shortly after the inoculations.
One out of 45 piglets in the NCG was euthanized (D22)
(Release®300 mg/ml, WDT, Garbsen, Germany) due to
nervous symptoms and lateral decubitus. Necropsy was
performed and Haemophilus parasuis was isolated in pure
culture from the meninges and pericardium. All animals
in the PCG coughed, showed macroscopic lung lesions
and seroconverted. Mycoplasma hyopneumoniae-DNA
was detected in 19 out of 20 animals from this group.
Clinical and performance parameters
The results of the clinical parameters are summarized in
Table 1. There was no coughing in the NCG throughout
the study. The RDS24–53 was 1.20 ± 0.83 and 0.55 ± 0.42
for the PCG and VG (P < 0.001), respectively. This
corresponds with a reduction of 52.9% in RDS when vac-
cinating the piglets compared to the PCG. All groups
significantly differed from each other. These results and
the RDS 1–53 and RDS 1–23 results are shown in Table 1
and Fig. 1.
The average group weight at D0, D24 and D53 and the
ADG calculated during these three periods (0–24, 24–53
and 0–53 days of age) for each group are shown in Table 1.
Macroscopic and histopathologic lung lesions
There were no macroscopic lung lesions in the NCG.
The MLL of the PCG and VG was 7.56 ± 4.73 and
0.68 ± 0.73, respectively (P < 0.001) (Table 1). A reduc-
tion of 91.0% in MLL of the VG was observed compared
to the PCG. The histopathological lung lesion scoring in
the NCG, PCG and VG was 1.31 ± 0.18, 3.32 ± 0.85 and
1.92 ± 0.47 (P < 0.001), respectively. The percentage of
lung area occupied by air (percentage air) was 47.72 ± 7.29,
34.49 ± 8.22 and 45.23 ± 5.99% for the NCG, PCG and VG
(P < 0.001), respectively. For the MLL and percentage of
air analysis, the PCG was significantly different from the
VG and NCG. For the histopathology score, all groups sig-
nificantly differed from each other (Table 1).
Quantitative PCR for detection of M. hyopneumoniae DNA
The samples of the NCG remained negative throughout
the study. The number of log copies of M. hyopneumo-
niae detected in the bronchoalveolar lavage fluid with
qPCR in the PCG and VG were: 3.99 ± 1.20 (PCG) and
1.78 ± 1.36 (VG) (P < 0.001) at D53 (Table 1). The re-
sults of D39 and the percentage of animals that tested
positive by qPCR are also shown in Table 1.
Immunological parameters on bronchoalveolar lavage
fluid
All results of the immunological parameters on D39 and
D53 are summarized in Table 2.
Detection of M. hyopneumoniae-specific antibodies in
bronchoalveolar lavage fluid
There were no significant differences in the Ig G and Ig
A results between the three groups at D39 (Table 2).
At D53, the Ig G values were 0.38 ± 0.17, 2.25 ± 0.91
and 2.41 ± 0.88 for the NCG, PCG and VG, respectively
(P = 0.005). At D53, the results for Ig A were
0.18 ± 0.14, 2.10 ± 0.75, 2.08 ± 0.58 for the NCG, PCG
and VG, respectively (P = 0.005). Both the Ig G and Ig A
concentrations at D53 of the PCG and VG differed sig-
nificantly from the NCG.
Detection of cytokines in bronchoalveolar lavage fluid
The TNF-α, IL-1 and IL-6 results at D39 and D53
are shown in Table 2. There were no significant dif-
ferences obtained in the TNF-α- results (pg/ml) at
D39, nor at D53.
At D53, the IL-1 concentration in the bronchoalveolar
lavage fluid was 17.61 ± 1.98, 1283.39 ± 1075.65 and
53.04 ± 54.23 pg/ml in the NCG, PCG and VG, respect-
ively (P < 0.001).
At D39, the IL-6 concentration was significantly differ-
ent between the PCG and VG (Table 2). At D53, the IL-
6 concentration was 148.10 ± 8.89, 493.35 ± 494.70 and
259.80 ± 333.38 for the NCG, PCG and VG, respectively
(P = 0.004) with significantly higher concentrations in
the PCG compared to the NCG and VG.
Serology
The serological results are presented in Table 1. All pigs
of the NCG remained serologically negative throughout
the study at D53 all pigs of the PCG and VG were sero-
logically positive for M. hyopneumoniae. The OD values
at D53 were 0.90 ± 0.10, 0.23 ± 0.11 and 0.087 ± 0.041
in the NCG, PCG and VG, respectively (P < 0.001). In
the VG significantly lower OD-values were detected,
thus higher M. hyopneumoniae specific antibodies com-
pared to the PCG and NCG (Table 1).
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Bacteriological culture
Streptococcus suis was isolated in only one pig of the
PCG. No relevant bacterial growth was observed in all
other lung samples.
Discussion
This study showed that the vaccine was efficacious for
the most part against an experimental challenge with
both a low and highly virulent M. hyopneumoniae strain.
The vaccinated pigs coughed significantly less, showed
significantly less lung lesions, a significantly lower num-
ber of log copies in the bronchoalveolar fluid at euthan-
asia was shown and the IL-1 and IL-6 concentrations at
euthanasia were lower compared to the non-vaccinated
inoculated pigs.
The challenge infection was performed with two gen-
etically different [27] M. hyopneumoniae isolates. The
virulence of these strains was evaluated by Vicca et al.
Table 1 Results of different parameters in the different experimental groups
Parameter Experimental Groups
NCG (# = 5) PCG (# = 20) VG (# = 20) P-value
RDS
D1–53 0 ± 0 a 0.68 ± 0.41b 0.32 ± 0.86 c <0.001
D1–23 0 ± 0 a 0 ± 0 a 0.017 ± 0.060 a 0.983
D24–53 0 ± 0 a 1.20 ± 0.83 b 0.55 ± 0.42 c <0.001
Weight ± SD
D0 7.04 ± 1.22a 6.97 ± 0.84 a 7.04 ± 1.02 a 0.966
D24 15.25 ± 3.96 a 16.39 ± 2.16 a 15.61 ± 2.96 a 0.581
D53 36.51 ± 8.63 a 34.63 ± 6.63 a 34.27 ± 5.35 a 0.808
ADG (g/pig/d)
D0–24 357 ± 123 a 393 ± 62.8 a 357 ± 92.0 a 0.372
D24–53 733 ± 194 a 629 ± 199 a 643 ± 102 a 0.504
D0–53 563 ± 144 a 522 ± 121 a 514 ± 87.0 a 0.714
MLL, histopathology and air analysis D53
MLL 0 ± 0 a 7.56 ± 4.73 b 0.68 ± 0.73 a <0.001
Histopathology 1.31 ± 0.18 a 3.32 ± 0.85 b 1.92 ± 0.47 c <0.001
Percentage of air (%) 47.72 ± 7.29 a 34.49 ± 8.22 b 45.23 ± 5.99 a <0.001
log copies of M. hyopneumoniae DNA/ml BALF (qPCR) ± SD
D39 0.36 ± 0.64 a 1.81 ± 1.32 a 1.23 ± 1.61 a 0.062
D53 0.40 ± 0.43 a 3.99 ± 1.20 b 1.78 ± 1.36 a <0.001
Percentage of M. hyopneumoniae qPCR positive samples in BALF (#positive samples/total number of samples)
D39 (0/4) 0a (14/20) 70b (7/20) 35c <0.01
D53 (0/4) 0a (19/20) 95b (12/20) 60c <0.001
M. hyopneumoniae specific AB expressed in OD-values ± SD in serum
D1 1.51 ± 0.037 a 1.48 ± 0.058 a 1.48 ± 0.16 a 0.578
D24 0.91 ± 0.044 a 0.95 ± 0.069 a 0.50 ± 0.17 b <0.001
D53 0.90 ± 0.10 a 0.23 ± 0.11 a 0.087 ± 0.041 b <0.001
Percentage of ELISA M. hyopneumoniae positive samples in serum
D1 (0/5) 0a (0/20) 0a (0/20) 0a 1.000
D24 (0/4) 0a (0/20) 0a (15/20) 75b <0.001
D53 (0/4) 0a (20/20) 100b (20/20)100b <0.001
The respiratory disease score (RDS), body weight, average daily gain (ADG), M. hyopneumoniae specific antibodies, macroscopical lung lesions (MLL),
histopathology and air analysis, log copies of M. hyopneumoniae DNA (qPCR), percentage of of M. hyopneumoniae qPCR positive samples, M. hyopneumoniae
specific AB expressed in OD-values and Percentage of ELISA M. hyopneumoniae positive samples
a,b,cDifferent superscripts in one row are statistically different (P < 0.05)
NCG negative control group, PCG positive control group, VG vaccination group, SD standard deviation, D Day of the study, ADG average daily gain, kg kilogram,
RDS respiratory disease score, M. hyopneumoniae Mycoplasma hyopneumoniae, AB antibodies, OD optical densities, # number, MLL macroscopic lung lesions, qPCR
quantitative polymerase chain reaction, DNA DeoxyriboNucleic Acid, BALF bronchoalveolar lavage fluid
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[16] and both strains were characterised at proteomic
and genomic level by Calus et al. [28], Vranckx et al. [4]
and Stakenborg et al. [29], respectively. The double chal-
lenge infection model was successful as all animals in the
PCG showed lung lesions, coughed and seroconverted. In
19 out of 20 animals of the PCG at euthanasia, DNA of
M. hyopneumoniae was detected in the bronchoalveolar
lavage fluid. It is well known that there can be quite some
variation between pigs in terms of responses to an experi-
mental infection. Why this particular pig tested negative is
not known. Possibly, the conditions for multiplication of
the M. hyopneumoniae strains were not optimal in that
pig. Although bronchoalveolar fluid is an appropriate sam-
pling technique to detect M. hyopneumoniae during the
early stages of infection, it fails to recover some positive
animals in case of chronic infection [30]. Taken these
factors into consideration, this might be the reason
why, although the pig was challenged, it did not test
positive. Although comparing to other experimental
settings should be done with caution, clinical symptoms
and lung lesions were comparable or more severe than
the single F7.2C challenge model performed in our
research group [12, 16, 24, 25, 31–38] and the standard
deviation was lower [16, 31–35]. It was shown that
most pigs in the field are simultaneously infected with
two or sometimes three genetically different M. hyop-
neumoniae strains and that when batches of slaughter
pigs are infected with more than one M. hyopneumo-
niae strain, this can result in more (severe) pneumonia
lesions and fissures [6]. The current experimental set-
ting might therefore better resemble the field situation
than infection with a single strain. Finally, it was shown
that anesthetizing and inoculating the piglets with
seven ml of inoculum on two consecutive days is feas-
ible, as none of the piglets showed adverse reactions or
died during or shortly after the inoculations.
Fig. 1 Average respiratory disease score (RDS) during the trial for
the negative control group (NCG), positive control group (PCG) and
vaccination group (VG). The average RDS was assessed daily from
day 1 until day 53. The piglets were vaccinated at D1 and the
inoculations were performed at D24 and D25
Table 2 Immunological parameters measured in the BALF at D39 and D53
Parameter Experimental groups
NCG (# = 5) PCG (# = 20) VG (# = 20) P-value
Ig G ± SD (OD-values)
D39 0 ± 0 a 0.069 ± 0.14 a 0.31 ± 0.65 a 0.366
D53 0.38 ± 0.17 a 2.25 ± 0.91 b 2.41 ± 0.88 b 0.005
Ig A ± SD (OD-values)
D39 0 ± 0 a 0.067 ± 0.18 a 0.55 ± 0.99 a 0.359
D53 0.18 ± 0.14 a 2.10 ± 0.75 b 2.08 ± 0.58 b 0.005
TNF-α ± SD (pg/ml)
D39 23.61 ± 1.74 a 18.56 ± 4.40 a 21.12 ± 4.56a 0.029
D53 16.03 ± 1.10 a 14.53 ± 5.95 a 15.15 ± 2.40a 0.065
IL-1 ± SD (pg/ml)
D39 32.47 ± 1.77 a 239.63 ± 511.35 a 247.13 ± 606.71a 0.367
D53 17.61 ± 1.98 a 1283.39 ± 1075.65 b 53.04 ± 54.23 a <0.001
IL-6 ± SD (pg/ml)
D39 130.33 ± 18.65 ab 242.24 ± 122.23 a 164.64 ± 84.48 b 0.03
D53 148.10 ± 8.89 a 493.35 ± 494.70 b 259.80 ± 333.38 a 0.004
D39: two weeks after challenge
D53: necropsy
a,bDifferent superscripts in one row are statistically different (P < 0.05)
NCG negative control group, PCG positive control group, VG vaccination group, SD standard deviation, D Day of the study, OD optical densities, # number
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The pigs in the vaccinated group coughed significantly
less (−53%) from inoculation until euthanasia compared
to the positive control group, demonstrating the efficacy
of the vaccine. The degree of coughing is an important
efficacy parameter [39, 40] not only under experimental
but also under field conditions. A coughing index can be
used to estimate if a higher prevalence of enzootic pneu-
monia in a herd might be present [41] and to determine
the most optimal timing of serological sampling of the
pigs or collecting bronchoalveolar fluid to be tested with
PCR [41, 42]. In this study, no statistical significant dif-
ferences were observed in the parameters weight and
ADG, although the pigs in the VG grew slightly faster
compared to the PCG from day of inoculation until day
of euthanasia onwards. Although the parameter weight
and ADG are of great use to evaluate in field circum-
stances, in experimental trials they are merely of de-
scriptive value as the low number of animals used, the
duration of the trial and the sometimes high standard
deviations are the reason why only numerical differences
are found [10, 16, 31].
The MLL score in the vaccinated pigs was very low
(0.68) and statistically different from the PCG (7.56),
implying a reduction with 91%, and demonstrating the
efficacy of the vaccine. A recent field study showed that
when pigs are infected with more strains, more lung le-
sions are detected [6]. When comparing the MLL scores
from the double inoculated challenge in PCG with those
from challenged unvaccinated pigs in the single inocula-
tion model from previous studies (highest MLL was 6.69
for F7.2C challenge in Villarreal et al., [25]), higher MLL
in this study are obtained. However, comparing different
experimental settings, should be done with caution. To
make a true comparison, the resulting MLL from the
double infection model should be compared with the
single inoculation model from both strains F7.2C and
F1.12A in one experimental setting.
In the vaccinated animals significantly less lymphohis-
tiocytic infiltration (1.92) was observed compared to the
PCG (3.32). These results are in accordance with the
results of previous studies [25, 31, 32]. Although many as-
pects of the effect of vaccination on the immunological re-
sponse remain unclear [43], the present results confirm
that vaccination has a regulating function on the immune
system, causing less infiltration of macrophages in the
lung tissue [34]. A significantly lower area occupied by air
or air percentage was measured in the non-vaccinated
animals of PCG (34.49%) compared to VG (45.23%).
Infection with M. hyopneumoniae results in intrabronch-
iolar- and bronchial exudate and infiltration of lymphohis-
tiocytic cells in the lung tissue. These responses may
result in compressing the airways and alveoli, leading to
less air volume in the lungs [15]. Vaccination also signifi-
cantly reduced the log copies of M. hyopneumoniae DNA
in the bronchoalveolar lavage fluid compared to the non-
vaccinated animals (1.78 versus 3.99), which may lead
to less shedding of M. hyopneumoniae in vaccinated
pigs. Similar reductions were found in previous studies
[34, 44]. These results, although very promising, con-
firm once more that vaccination is not able to prevent
pigs from being colonized as commonly known [8].
Mycoplasma hyopneumoniae-specific antibody (Ig G
and Ig A) levels in tracheo-bronchial washings were not
significantly different between vaccinated and non-
vaccinated pigs. Our findings are in accordance with
Djordevic et al. (1997) [24, 45], but Thacker et al. (2000)
suggested that secretion of M. hyopneumoniae- anti-
bodies induced by vaccination into the bronchoalveolar
washings might be implied in resolving mycoplasmal
pneumonia [43, 46, 47]. Further research is needed to
clarify a possible protective role of M. hyopneumoniae-
specific antibodies in trachea-bronchial washings.
There were no significant differences between the vacci-
nated and non-vaccinated animals for the TNF-α concen-
tration in the bronchoalveolar fluids. In the study of
Marchioro et al. [24], vaccination significantly decreased
TNF-α concentrations, but the difference was small and
only borderline significant. This highlights the need to fur-
ther elucidate the pathogenesis of M. hyopneumoniae and
the exact mechanisms in which way M. hyopneumoniae-
bacterins provide protection to the animal.
The cytokines IL-1 and IL-6, next to TNF-α are pro-
inflammatory cytokines [48]. Previous research stated
that they mediate lymphocyte infiltration and activation
in the pneumonic lung [49, 50], and thus are associated
with the induction of pneumonia lesions [24, 51, 52].
The pro-inflammatory cytokines TNF-α, IL-1 and IL-6
were correlated with MLL at D39 and D53. The param-
eter TNF-α was weakly and not significantly correlated
with MLL on both sampling days (D39 and D53). Inter-
leukin 1 was strongly and significantly correlated with
MLL at euthanasia, and IL-6 was moderately and signifi-
cantly correlated with MLL on D39 and D53. This sug-
gests that the vaccine shows a protective effect mainly
by modulation of the pro-inflammatory cytokines IL-1
and IL-6, but not TNF-α (data not shown). The IL-1
concentration and the standard deviation in the non-
vaccinated pigs was very high. This result is in accord-
ance with the result of Meyns et al. [38] at 28 days post
inoculation with the F7.2C isolate. One can conclude
that a part of the piglets in the non- vaccinated group
showed very high IL-1 levels. The reason why this oc-
curred is not clear, however the individual susceptibility
of the pig to an M. hyopneumoniae infection must be
kept into account causing the challenge infection to be
more successful. The IL-1 and IL-6 concentrations at
necropsy in the vaccinated pigs were significantly lower
than in the non-vaccinated pigs and not significantly
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different from the levels in negative control group. These
results substantiate the statement that was made in
Marchioro et al. [24] based on the IL-1 result of the vacci-
nated pigs at D36 that IL-1 and IL-6 may have a regula-
tory role upon M. hyopneumoniae vaccination [24].
In this study, the pigs were vaccinated approximately
4 weeks before challenge, as vaccination is most likely to
be effective if active immunity is established before the
piglets are exposed to the pathogen. Under field condi-
tions, however, the time between vaccination and infection
is not known, and very likely highly variable between pigs.
Hence, it is possible that the vaccine used in the field is
less efficacious when the timing of vaccination is not opti-
mal. As this is an experimental study, the results cannot
be extrapolated as such to field conditions. Under field cir-
cumstances, more factors challenging the efficacy of a vac-
cine are present, compared to the controlled environment
of an experimental facility. First, multi-factorial and multi-
pathogen enzootic pneumonia outbreaks are typically
found in the field, rather than isolated M. hyopneumoniae
outbreaks [2]. The piglets originated from a herd free of
important diseases which can influence the outcome of
an M. hyopneumoniae infection, such as PRRSv Pas-
teurella multocida, and Actinobacillus pleuropneumo-
niae. [1, 53, 54] and according to some authors
infection with certain pathogens can determine the effect-
iveness of M. hyopneumoniae vaccination as well [54–56].
Second, the impact of weaning stress should be taken into
account when vaccinating piglets at weaning age in the
field. Although the impact of weaning stress on vaccine ef-
ficacy might not be clear [31], it could not have influenced
the efficacy of the vaccine, as the pigs were transported
and vaccinated some days after weaning. Thirdly, passively
acquired maternal derived immunity could not have influ-
enced the efficacy of the vaccine as these piglets were ori-
ginating from a herd free of M. hyopneumoniae and no
vaccinations against M. hyopneumoniae in the sows, nor
the piglets were performed. This is a double sided given.
On the one hand, Hodgins et al. [57] stated that maternal
antibodies in the piglets were associated with reduced
antibody responses to vaccination. On the other hand, the
piglets in the study could not benefit from the passively
transferred cell-mediated immunity. Bandrick et al. [30]
showed that vaccination of piglets against M. hyopneumo-
niae in the face of antigen-specific maternal-derived im-
munity results in cell-mediated immunity priming and
anamnestic cell-mediated immunity responses following
the exposure to M. hyopneumoniae antigen. On the other
hand, some factors in the experimental study were com-
parable to field circumstances or challenged the vaccine
more. First, although the piglets were free from certain
pathogens, other than that, the piglets were originating
from a conventional farm. Second: the piglets were trans-
ported from the herd of origin to the experimental
facilities and the piglets needed to establish a new hier-
archy after comingling. These events are associated with
stress, which might influence the efficacy of the vaccine.
This can resemble the stress that piglets experience in the
field, when sorted and moved from one facility to another
in a multi-site production system. Thirdly: the vaccine
was highly challenged in this experimental study, because
as stated by Villarreal et al., [35] and Meyns et al. [37], it
can be assumed that the M. hyopneumoniae challenge
dose used to infect the pigs was higher than might be
reached under natural conditions resulting in a faster and
higher colonization level and presumably challenging the
vaccine more than under field circumstances [35, 37]. Al-
though extrapolation of the efficacy testing of the vaccine
results obtained in experimentally M. hyopneumoniae in-
fected pigs should be done with caution, this infection
model enabled to study the effect of the vaccine in M.
hyopneumoniae infected pigs in a reproducible and stan-
dardized way.
Conclusion
Using a double challenge infection model with a low and
highly virulentM. hyopneumoniae strain, one-dose vaccin-
ation of piglets was efficacious for the most part, as
coughing was reduced by more than 50% and macroscopi-
cal lung lesions by 91%. In addition, the lymphohistiocytic
infiltration in lung tissue was lower, the number of log
copies of M. hyopneumoniae DNA detected in bronchoal-
veolar lavage fluid and the IL-1 and IL-6 concentrations at
euthanasia were lower in the vaccinated animals com-
pared to non-vaccinated animals.
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